Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 15 Saturday Friday Sunday Monday Tuesday Publication Only MONDAY, JUNE 3 RD 1:15pm - 4:30pm Central Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 1:15 - 2:45pm 1:15 - 1:21pm Arie Crown Theater Oral 3509 Final results of a phase 2 study of tucatinib and trastuzumab for HER2- positive mCRC (MOUNTAINEER). Strickler J Paulson A Gastrointestinal Cancer—Colorectal and Anal 1:15 - 2:45pm 1:27 - 1:33pm Hall B1 Oral 5011 ARV-766, a PROteolysis TArgeting Chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): initial results of a phase 1/2 study Petrylak D McKean M Genitourinary Cancer— Prostate, Testicular, and Penile 1:15 - 2:45pm 2:27 - 2:33pm Arie Crown Theater Oral 3517 Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study. Parikh A Spigel D, Ulahannan S Gastrointestinal Cancer—Colorectal and Anal 1:15 - 2:45pm 1:51 - 1:57pm S102 Oral 11013 5-year multicenter analysis of clinical trial participation and total cost of care for older adults with cancer Subbiah I Subbiah I Quality Care/Health Services Research 1:30 - 4:30pm Hall A Poster 8640 Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline- recommended biomarker selection in non-small cell lung cancer (NSCLC). Subbiah V Subbiah V Lung Cancer— Non-Small Cell Metastatic 1:30 - 4:30pm Hall A Poster 12084 Patient-reported symptom interference with activity- and mood- related functioning prior to start of an early-phase oncology combination trial including immune checkpoint blockade. George G Subbiah V Symptom Science and Palliative Care 1:30 - 4:30pm Hall A Poster 8556 A phase-1 dose escalation and expansion study of EP0031, a next- generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors. Garralda E Wang J, Spigel D, Subbiah V Lung Cancer—Non- Small Cell Metastatic 1:30 - 4:30pm Hall A Poster 8558 MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study Johnson M Johnson M Lung Cancer - Non- Small Cell Metastatic